Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Wednesday 16 November, 2005

XTL Biopharm Ltd

Data demonstrating antiviral activity of XTL6865


 XTLbio announces data demonstrating the antiviral activity of one of the two  
   antibodies comprising XTLbio's lead Hepatitis C drug candidate - XTL6865    

Data presented yesterday at the 56th annual meeting of the American Association
               for the Study of Liver Diseases in San Francisco                

Rehovot, Israel; Wednesday 16 November 2005: XTL Biopharmaceuticals Ltd.
('XTLbio') (LSE: XTL; NASDAQ: XTLB; TASE: XTL) presented yesterday data from a
pilot Phase I/II clinical trial with Ab68, one of the two antibodies comprising
XTLbio's lead Hepatitis C drug candidate - XTL-6865.

This pilot study was conducted in patients with hepatitis C following liver
transplantation. Patients in this study were treated with 20, 40, 80, 120 or
240 mg doses of Ab68. Ab68 was administered once during the transplantation,
then up to 3 times during the first 24 hours following the transplantation,
then daily during the following 6 days, and then in a decreasing frequency
during the following 11 weeks.

During the period of daily dosing (the first 7 days following the
transplantation) reduction in viral load from baseline was greater in the two
highest dose groups (120 and 240 mg) compared to the placebo group. On day 1
following the transplantation (when Ab68 was administered 3 times) the median
reduction in viral load from baseline of the highest dose group (240 mg) was
1-log (90%) greater than the placebo group.

Thomas Schiano, MD, Medical Director of Adult Liver Transplantation and
Director of Clinical Hepatology at the Recanati/Miller Transplantation
Institute at Mount Sinai Medical Center commented: 'The results presented are
very encouraging, as they provide clinical demonstration that Ab68 - which is
one of the two antibodies comprising XTLbio's lead hepatitis C drug candidate -
XTL-6865 - has shown activity in reducing viral levels.'

The dual antibody product - XTL-6865 - is presently in Phase Ia clinical trial
in patients with chronic hepatitis C. Results from this trial are expected in
the second half of 2006

Link to the data presentation: www.xtlbio.com

About XTL-6865

XTL-6865 is XTLbio's lead Hepatitis C drug candidate, currently in a Phase Ia
clinical trial in patients with chronic hepatitis C.

XTL-6865 is a dual-antibody therapeutic developed for two potential
indications: preventing hepatitis C recurrence following liver transplantation
and preventing relapse following treatment of patients with chronic Hepatitis
C.

The two antibodies comprising XTL-6865 - Ab68 and Ab65 - were developed
sequentially, and Ab68 was available for clinical evaluation approximately 2
years before Ab65. This enabled XTLbio to conduct pilot studies with Ab68 alone
to evaluate its safety and pharmacokinetic properties in patients with chronic
hepatitis C, and in patients with hepatitis C following liver transplantation.

The pilot studies with Ab68 in patients with chronic hepatitis C provided
preliminary evidence of antiviral activity of Ab68. In the multi-dose pilot
study in patients with chronic hepatitis C, a third of the patients
demonstrated at least once an equal to or greater than 1-log (90%) reduction in
viral load following the administration of Ab68.

The pilot study in patients following liver transplantation - the results of
which are described above - provided further data demonstrating the antiviral
activity of Ab68.

Phase 1a trial with the dual antibody drug candidate - XTL-6865 - was initiated
in September 2005 in patients with chronic hepatitis C. Results from this trial
are expected in the second half of 2006.

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

About XTL Biopharmaceuticals Ltd.

Established in 1993, XTL Biopharmaceuticals Ltd. (LSE: XTL; NASDAQ: XTLB; TASE:
XTL) is a biopharmaceutical company engaged in the acquisition, development and
commercialization of pharmaceutical products for the treatment of infectious
diseases, particularly the prevention and treatment of hepatitis B and C.

Cautionary Statement

Some of the statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the US Private Securities Litigation Reform Act of
1995. Among the factors that could cause our actual results to differ
materially, and therefore affect interest by investors in our securities, are
the following: the results of the trials of Ab68 are not necessarily indicative
of the results we may have in future trials of the Ab68 antibody or of the
Phase 1a and 1b trials of XTL6865, as there are many factors affecting those
future studies that could yield more inconclusive or negative results; and
other risk factors identified from time to time in our reports filed with the
various regulatory bodies. Any forward-looking statements set forth in this
press release speak only as of the date of this press release. We do not intend
to update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release and prior
releases are available at www.xtlbio.com. The information in our website is not
incorporated by reference into this press release and is included as an
inactive textual reference only.


                                                                                                                                                                                                                                               

a d v e r t i s e m e n t